← Back to patent-cliff list
CAS 1816998-83-0
1-[(3S)-3-[[tert-Butyl(dimethyl)silyl]oxy]piperidin-1-yl]prop-2-en-1-one
Codes：(VIb)461018-6-a
Application context (from source-drug indications)
华氏巨球蛋白血症伊布替尼慢性淋巴细胞白血病伊布替尼套细胞淋巴瘤伊布替尼移植物抗宿主病伊布替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 伊布替尼Ibrutinib | Tier A — Act now | 2027 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3S)-1-(tert-Butoxycarbonyl)-3-hydroxypiperidine→(S)-1-tert-Butoxycarbonyl-3-(p-toluenesulfonyloxymethyl)piperidine→tert-Butyl (3S)-3-[[tert-butyl(dimethyl)silyl]oxy]piperidine-1-carboxylate→(3S)-Piperidin-3-yl 4-methylbenzenesulfonate→(3S)-3-[[tert-Butyl(dimethyl)silyl]oxy]piperidine→2-Propenoyl chloride→2-Propenoic acid→(3S)-1-Acryloylpiperidin-3-yl 4-methylbenzenesulfonate→1-[(3S)-3-[[tert-Butyl(dimethyl)silyl]oxy]piperidin-1-yl]prop-2-en-1-one→(3S)-1-Acryloylpiperidin-3-yl 4-nitrobenzenesulfonate→3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.